Hot Topic: 340B Program

IPD’s team of experts—Jeff Casberg, MS, RPh, Leslie Fish, RPh, PharmD, Andy Levitsky, PharmD, BCPS, Steven Johnson, PharmD, Kate Cook, PharmD, CAHIMS, CMAS, and Scott Allen, JD—recently sat down to discuss the developments and challenges within the 340B drug pricing program, including perspectives from pharmaceutical manufacturers, payers, federal government, hospitals, and legal analysts. In addition, this episode provides insight into how recent court cases and proposed legislative actions might impact the 340B program.

Key topics include:

Historical Context and Growth: The 340B program has grown from 8100 covered entity sites in 2000 to over 50,000 in 2020, with program savings estimated at nearly $54 billion in 2022.

Stakeholder Perspectives: Our experts share perspectives from pharmaceutical manufacturers, payers, federal government, and hospitals on the impacts of the 340B program, including issues related to transparency and accountability.

Challenges: These include drug diversion, duplicate discounts, and the complexities of contract pharmacy arrangements.

Legal and Legislative Updates: We summarize recent court decisions and proposed legislation such as the SUSTAIN 340B Act and 340B ACCESS Act , aimed at improving the program’s transparency and integrity.